Anthem Blue Cross and Blue Shield | CommercialOctober 1, 2024
Notice of material change/amendment to contract
Medical Policy and Clinical Guideline updates
The following new revised Medical Policies and Clinical Guidelines were endorsed at the August 8, 2024, Medical Policy & Technology Assessment Committee (MPTAC) meeting. These, and all Anthem’s Medical Policies and Clinical Guidelines, are available at anthem.com. Select For Providers. Under the Provider Resources heading, select Policies, Guidelines & Manuals. Select your state. Then, select View Medical Policies & Clinical UM Guidelines.
To view Medical Policies and Clinical Utilization Management Guidelines applicable to members enrolled in the Blue Cross and Blue Shield Service Benefit Plan (commonly referred to as the Federal Employee Program® [FEP]), visit fepblue.org > Policies & Guidelines.
Medical Policy updates
New Medical Policies effective January 1, 2025
The following policies are new:
- DME.00052 Brain Computer Interface Rehabilitation Devices*
- LAB.00051 Per- and Polyfluoroalkyl Substances (PFAS) Testing*
- MED.00150 Hepzato Kit™ (melphalan hepatic delivery system)*
Revised Medical Policies effective January 1, 2025
The policies below were revised and might result in services that were previously covered but may now be found to be either not medically necessary and/or investigational:
- DME.00011 Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices*
- LAB.00026 Systems Pathology and Multimodal Artificial Intelligence Testing for Cancerous and Precancerous Conditions*
- MED.00134 Non-invasive Heart Failure and Arrhythmia Management and Monitoring Systems
- MED.00148 Gene Therapy for Metachromatic Leukodystrophy
- SURG.00032 Patent Foramen Ovale and Left Atrial Appendage Closure Devices*
Clinical Guideline updates
Adopted Clinical Guideline effective January 1, 2025
The following guideline will be applied and might result in services that were previously covered but may now be found to be not medically necessary:
- CG-MED-97 Biofeedback and Neurofeedback*
* The applicable policy is attached to this article in PDF format.
Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
MEBCBS-CM-067810-24
ATTACHMENTS: DME.00052_Pub 10-01-2024 (original) (pdf - 0.13mb), LAB.00051_Pub 10-01-2024 (original) (pdf - 0.18mb), MED.00150_Pub 10-01-2024 (original) (pdf - 0.21mb), DME.00011_Pub 10-01-2024 (original) (pdf - 0.49mb), DME.00011_Pub 10-01-2024 (redline) (pdf - 0.68mb), LAB.00026_Pub 10-01-2024 (original) (pdf - 0.25mb), LAB.00026_Pub 10-01-2024 (redline) (pdf - 0.36mb), MED.00134_Pub 10-01-2024 (original) (pdf - 0.25mb), MED.00134_Pub 10-01-2024 (redline) (pdf - 0.36mb), MED.00148_Pub 10-01-2024 (original) (pdf - 0.19mb), MED.00148_Pub 10-01-2024 (redline) (pdf - 0.26mb), SURG.00032_Pub 10-01-2024 (original) (pdf - 0.42mb), SURG.00032_Pub 10-01-2024 (redline) (pdf - 0.7mb), CG-MED-97_Pub 06-28-2024 (original) (pdf - 0.34mb)
PUBLICATIONS: October 2024 Provider Newsletter
To view this article online:
Visit https://providernews.anthem.com/maine/articles/medical-policy-and-clinical-guideline-updates-22049
Or scan this QR code with your phone